Impact Biomedical Files Form F-4 For Proposed Zoar Business Combination

DSS Inc., a significant shareholder of Impact Biomedical Inc., said Zoar Limited filed an SEC Form F-4 registration statement related to a previously announced proposed business transaction. The filing marks a procedural regulatory step toward completing the transaction, but the article provides no valuation, timeline, financial terms, or expected closing date.